Chromosome Disorders  >>  lenalidomide  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lenalidomide / Generic mfg.
NCT00761449 / 2007-000450-31: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

Completed
2
28
Europe
lenalidomide, Revlimid
Nordic MDS Group
MDS, AML
12/09
12/09
LENAMAINT, NCT00720850 / 2007-002433-37: Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Terminated
2
10
Europe
lenalidomide, Revlimid
Technische Universität Dresden, Celgene Corporation
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
01/11
01/11
NCT00874978 / 2004-005101-29: The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Completed
2
36
Europe
lenalidomide, Revlimid, CC-5013
King's College Hospital NHS Trust
Myelodysplastic Syndromes
05/16
05/16
NCT03000634: 2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

Withdrawn
2
0
NA
Elotuzumab, Elo, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Decadron
University of Arkansas
Multiple Myeloma
05/23
05/23

Download Options